An Indiana CDMO with big-name clients sets up plans for lentiviral production site
An Indiana CDMO focused on gene therapy is cashing in on the industry’s hot streak and unveiling a master plan for a 75,000-square-foot lentiviral vector production site.
Genezen Laboratories broke ground on the construction of a new plant outside Indianapolis, IN. It will complete the first phase of construction — good for 25,000 square feet — by autumn 2021, and the rest of the facility will go online by early 2022, the company said in a release.
The facility will have several GMP production suites and capabilities for host cell expansion, host cell banking and viral vector production through a transient transfection and producer cell lines, the release said. The product will be filled into sterile bags on-site as well.
“The cell and gene therapy sector is evolving rapidly, and there’s growing demand for capacity and expertise,” CEO Bill Vincent said in a statement. “Building on recognized expertise in lentiviral and retroviral vector platforms, and leveraging the CDMO experience of our investor Ampersand, we are investing heavily to meet this need now, and in the future.”
Private equity firm Ampersand Capital Partners funded the majority of the project.
The company was founded in Indianapolis in 2014 and works close with Ken Cornetta from Indiana University.
Legend Biotech, Orchard Therapeutics and Gilead’s Kite are just some of the CDMO’s clients. Legend’s multiple myeloma treatment was placed in the fast lane by the FDA en route to a fall regulatory decision timeline.
Just last week, the company and its partner J&J announced that it would add on a new Belgian manufacturing facility in order to prepare for the filing of approval for cilta-cel, its investigational therapy for patients with relapsed and refractory multiple myeloma.